Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. of obinutuzumab with novel targeted agents. expression of the inhibitory Fc receptor FcRIIb on CGS-15943 manufacture target B-cells and… Continue reading Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal